Moderna announces that its mRNA influenza vaccine is more effective than conventional vaccines
Moderna Announces Positive Results from Phase 3 Trial of Seasonal Influenza Vaccine
https://www.modernatx.com/en-JP/press-release/2025/20250701
Moderna says mRNA flu vaccine sailed through trial, beating standard shot - Ars Technica
https://arstechnica.com/health/2025/07/moderna-says-its-mrna-seasonal-flu-shot-is-27-better-than-current-vaccine/
Moderna announced the results of a Phase 3 clinical trial of mRNA-1010, an mRNA vaccine for seasonal influenza, on June 30, 2025 local time. In this Phase 3 clinical trial, 40,805 subjects aged 50 years or older living in 11 countries were vaccinated with mRNA-1010 or a standard influenza vaccine and followed for a median period of six months.
Analysis of the results showed that mRNA-1010 had a 26.6% higher relative vaccine efficacy (rVE) than the standard vaccine in the overall population, 29.6% higher against influenza A H1N1 , 22.2% higher against influenza A H3N2 , and 29.1% higher against influenza B (Victoria lineage) .
Additionally, the safety and tolerability of mRNA-1010 was consistent with previous clinical trials, with most adverse reactions being minor. The most common adverse reaction was pain at the injection site, and other systemic adverse reactions commonly reported included fatigue, headache, and muscle pain. No significant differences were observed in non-specific adverse events, serious adverse events, or adverse events of particular interest after vaccination compared to the regular vaccine.
'The Phase 3 efficacy data announced today marks an important milestone in Moderna's efforts to reduce the influenza disease burden in older adults,' said Stephane Bancel, CEO of Moderna. 'This year's severe influenza season has highlighted the need for a more effective vaccine. An mRNA-based influenza vaccine has the potential advantage of being more precise in targeting circulating strains, allowing for a faster response in the event of a future influenza pandemic. It may also pave the way for the development of a combination vaccine with COVID-19.'
Moderna plans to present data from this Phase 3 clinical trial at upcoming conferences and to submit the results to a peer-reviewed journal, and will continue discussions with regulatory authorities around the world to seek regulatory approval for mRNA-1010.
Technology media Ars Technica points out that even promising vaccines like mRNA-1010 have an uncertain future because Robert F. Kennedy Jr., who heads the U.S. Department of Health and Human Services at the time of writing, is a vaccine skeptic. On June 9th local time, Kennedy announced that he had dismissed all 17 members of the advisory committee that issues official government recommendations on vaccinations.
Kennedy's Department of Health and Human Services has also announced that it will require all new vaccines to undergo placebo-controlled trials using a fake vaccine before they are approved for use, a move that experts say raises ethical concerns because it would require people with life-threatening infectious diseases to be given a fake, ineffective vaccine when there is already an approved vaccine available.
In addition, in May, the Department of Health and Human Services announced it would cancel a grant it had received for the production of Moderna's mRNA vaccine. A Health and Human Services spokesperson said, 'The reality is that mRNA technology has not yet been fully validated.'
Related Posts:
in Note, Posted by log1h_ik